Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research- New Zealand
doi 10.2147/ceor.s201621
Full Text
Abstract
Available in
Date
June 1, 2019
Authors
Publisher
Informa UK Limited